One research analyst has rated the stock with a sell rating, one has assigned a hold rating and six have assigned a buy rating to the company.
Seres Therapeutics Inc (NASDAQ:MCRB) holds the market capitalization of $503.24M along with 40.36M outstanding shares.
Working capital declines Seres Therapeutics Inc. has witnessed a decline in the working capital over the a year ago.
For this year, Seres Therapeutics, Inc. Based on the filings, last years Annual Earnings was, $-2.33.
Seres Therapeutics Inc (NASDAQ:MCRB) has been given an average rating of "Buy" by the eight ratings firms that are covering the stock. The higher price target estimate is at $18 while the lower price estimates are fixed at $12.
Many research firms have provided their ratings on Seres Therapeutics, Inc. The gastrointestinal drug serves as fecal transplant alternative and has sometimes been referred to as a "poop pill" though Seres Therapeutics has refused to encourage such a nickname. The stock surged to a 4-month high. The company has a 50 day moving average price of $9.69 and a 200 day moving average price of $10.73. For the stock, price target value has been calculated at $14.71 based on calls of 7 experts.
The stock has a high price target of $57 according to consensus of 17 analysts. Artal Group S.A. now owns 700,000 shares of the company's stock worth $6,930,000 after buying an additional 200,000 shares in the last quarter. Now 12.9% of the stock's total float is wrapped up in these bearish bets, representing roughly four weeks' worth of buying power, at MCRB's average daily pace. This year Company's Earnings per Share (EPS) growth is 72.20% and next year's EPS growth is 13.24%. Fidelity Management and Research Company is the second biggest holder with 6 million shares now valued at 60.47 million whilst Federated Global Inv Mgmt Corp has 2 million shares valued at 25.12 million. Investors might also notice that three month ago the Buy recommendations (6) outnumbered Sell recommendations (0).
Revenues for the year were $21.77 million. Renaissance Technologies LLC raised its stake in Seres Therapeutics by 35.0% in the fourth quarter. Ellington Management Group LLC acquired a new stake in Seres Therapeutics during the fourth quarter worth about $107,000. Renaissance Technologies LLC now owns 400,300 shares of the company's stock worth $3,963,000 after buying an additional 103,800 shares during the last quarter. Finally, Trexquant Investment LP raised its stake in shares of Seres Therapeutics by 147.5% in the fourth quarter. "Our prior SER-109 studies provided important new biological and clinical data that have advanced our pioneering microbiome therapeutic efforts". The company, which raised $134 million in a high-profile 2015 initial public offering, had been viewed as a pioneer in so-called bugs-to-drugs development after it reported positive results from an early-stage clinical study. Seres is also developing SER-262, the first ever synthetic microbiome therapeutic candidate, in a Phase 1b study in patients with primary CDI.